1. Characteristics and plasma SFRP5 levels of breast cancer patients.
| Characteristics | Cases (N=218) | P | |
| n | Mean (ng/mL) | ||
| SFRP5, secreted frizzled-related protein 5; BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth receptor 2; LN, lymph node; N/A, unknown. | |||
| Numbers of births | 0.586 | ||
| 0−1 | 112 | 42.44 | |
| ≥2 | 103 | 37.08 | |
| N/A | 3 | 95.24 | |
| Age of menarche (year) | 0.002 | ||
| ≤15 | 120 | 49.21 | |
| >15 | 78 | 29.43 | |
| N/A | 20 | 32.90 | |
| BMI (kg/m2) | <0.001 | ||
| <24.0 | 88 | 55.67 | |
| ≥24.0 | 130 | 30.46 | |
| Menopause status | 0.570 | ||
| Yes | 116 | 35.63 | |
| No | 102 | 46.33 | |
| Family history of breast cancer | 0.661 | ||
| Yes | 16 | 22.35 | |
| No | 198 | 41.42 | |
| N/A | 4 | 74.72 | |
| Histological grade | 0.559 | ||
| I−II | 134 | 45.25 | |
| III | 76 | 34.03 | |
| N/A | 8 | 26.00 | |
| TNM stage | 0.047 | ||
| I−II | 188 | 43.83 | |
| III | 25 | 18.30 | |
| N/A | 5 | 32.36 | |
| ER status | 0.962 | ||
| Positive | 182 | 43.43 | |
| Negative | 35 | 27.00 | |
| N/A | 1 | 9.81 | |
| PR status | 0.941 | ||
| Positive | 172 | 41.41 | |
| Negative | 46 | 37.73 | |
| HER2 status | 0.558 | ||
| Positive | 49 | 40.02 | |
| Negative | 146 | 34.62 | |
| N/A | 23 | 80.14 | |
| Ki67 status | 0.011 | ||
| <14% | 26 | 84.49 | |
| ≥14% | 192 | 34.70 | |
| Numbers of LN infiltration | 0.007 | ||
| 0−3 | 191 | 43.65 | |
| ≥4 | 22 | 16.33 | |
| N/A | 5 | 32.36 | |
| Molecular subtype | 0.610 | ||
| Luminal A | 20 | 51.41 | |
| Luminal B | 162 | 39.02 | |
| HER2 | 10 | 38.36 | |
| Basal like | 19 | 18.79 | |
| N/A | 7 | 109.81 | |